scholarly journals A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

2015 ◽  
Vol 7 (1) ◽  
Author(s):  
Haakon B Nygaard ◽  
Allison F Wagner ◽  
Garrett S Bowen ◽  
Susan P Good ◽  
Martha G MacAvoy ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
System Availability ◽  
Phase Ib ◽  
Dose Study

scholarly journals Functions of the Alzheimer’s Disease Protease BACE1 at the Synapse in the Central Nervous System

2016 ◽  
Vol 60 (3) ◽  
pp. 305-315 ◽  
Author(s):  
Kathryn M. Munro ◽  
Amelia Nash ◽  
Martina Pigoni ◽  
Stefan F. Lichtenthaler ◽  
Jenny M. Gunnersen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
The Central Nervous System

Nerve Growth Factor (NGF) in the Central Nervous System: Implications for the Treatment of Alzheimer’s Disease

Brain Repair ◽  
1990 ◽  
pp. 99-112
Author(s):  
Dan Lindholm ◽  
Christine Bandtlow ◽  
Matthias Spranger ◽  
Bastian Hengerer ◽  
Michael Meyer ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Nerve Growth ◽  
The Central Nervous System

scholarly journals AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease

2018 ◽  
Vol 29 (1) ◽  
pp. 24-47 ◽  
Author(s):  
Jonathan B. Rosenberg ◽  
Michael G. Kaplitt ◽  
Bishnu P. De ◽  
Alvin Chen ◽  
Thomas Flagiello ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Gene Therapy ◽  
Central Nervous System ◽  
Nervous System

scholarly journals Peripheral versus central nervous system APOE in Alzheimer’s disease: Interplay across the blood-brain barrier

2019 ◽  
Vol 708 ◽  
pp. 134306 ◽  
Author(s):  
Dustin Chernick ◽  
Stephanie Ortiz-Valle ◽  
Angela Jeong ◽  
Wenhui Qu ◽  
Ling Li
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Blood Brain

scholarly journals CX3CL1/CX3CR1 in Alzheimer’s Disease: A Target for Neuroprotection

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Peiqing Chen ◽  
Wenjuan Zhao ◽  
Yanjie Guo ◽  
Juan Xu ◽  
Ming Yin
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Central Nervous System ◽  
Nervous System ◽  
Early Diagnosis ◽  
Vital Role ◽  
Therapeutic Interventions ◽  
Chemokine Ligand ◽  
The Central Nervous System ◽  
Receptor Cx3cr1

CX3C chemokine ligand 1 (CX3CL1) is an intriguing chemokine belonging to the CX3C family. CX3CL1 is secreted by neurons and plays an important role in modulating glial activation in the central nervous system after binding to its sole receptor CX3CR1 which mainly is expressed on microglia. Emerging data highlights the beneficial potential of CX3CL1-CX3CR1 in the pathogenesis of Alzheimer’s disease (AD), a common progressive neurodegenerative disease, and in the progression of which neuroinflammation plays a vital role. Even so, the importance of CX3CL1/CX3CR1 in AD is still controversial and needs further clarification. In this review, we make an attempt to present a concise map of CX3CL1-CX3CR1 associated with AD to find biomarkers for early diagnosis or therapeutic interventions.

Sign in / Sign up

Export Citation Format

Share Document